These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12204662)

  • 1. Measuring the clinical response. What does it mean?
    Therasse P
    Eur J Cancer; 2002 Sep; 38(14):1817-23. PubMed ID: 12204662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring response in solid tumors: comparison of RECIST and WHO response criteria.
    Park JO; Lee SI; Song SY; Kim K; Kim WS; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Lee KS; Park K
    Jpn J Clin Oncol; 2003 Oct; 33(10):533-7. PubMed ID: 14623923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria.
    Assouline S; Meyer RM; Infante-Rivard C; Connors JM; Belch A; Crump M; Kouroukis CT; Eisenhauer E
    Leuk Lymphoma; 2007 Mar; 48(3):513-20. PubMed ID: 17454591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A statistical simulation study finds discordance between WHO criteria and RECIST guideline.
    Mazumdar M; Smith A; Schwartz LH
    J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
    Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
    Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrepancy in the assessment of tumor response in patients with pancreatic cancer: WHO versus RECIST criteria.
    Ahn SH; Garewal HS; Dragovich T
    J BUON; 2008; 13(3):359-62. PubMed ID: 18979550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New guidelines to evaluate the response to treatment in solid tumors].
    Duffaud F; Therasse P
    Bull Cancer; 2000 Dec; 87(12):881-6. PubMed ID: 11174117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring response in a post-RECIST world: from black and white to shades of grey.
    Michaelis LC; Ratain MJ
    Nat Rev Cancer; 2006 May; 6(5):409-14. PubMed ID: 16633367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practice and progress in kidney cancer: methodology for novel drug development.
    Rini BI; Weinberg V; Small EJ
    J Urol; 2004 Jun; 171(6 Pt 1):2115-21. PubMed ID: 15126769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Satraplatin: BMS 182751, BMY 45594, JM 216.
    Drugs R D; 2007; 8(2):125-32. PubMed ID: 17324011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resisting RECIST-Uniformity Versus Clinical Validity.
    Wilson MK; Friedlander ML; Lheureux S; Small W; Poveda A; Pujade-Lauraine E; Karakasis K; Bacon M; Bowering V; Chawla T; Oza AM
    Int J Gynecol Cancer; 2017 Oct; 27(8):1619-1627. PubMed ID: 28692635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria.
    Trillet-Lenoir V; Freyer G; Kaemmerlen P; Fond A; Pellet O; Lombard-Bohas C; Gaudin JL; Lledo G; Mackiewicz R; Gouttebel MC; Moindrot H; Boyer JD; Chassignol L; Stremsdoerfer N; Desseigne F; Moreau JM; Hedelius F; Moraillon A; Chapuis F; Bleuse JP; Barbier Y; Heilmann MO; Valette PJ
    Br J Radiol; 2002 Nov; 75(899):903-8. PubMed ID: 12466256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Principles and practice of clinical phase II studies].
    Dittrich C
    Onkologie; 2008; 31 Suppl 2():46-52. PubMed ID: 18487869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot.
    Bruix J
    J Hepatol; 2021 Jun; 74(6):1483-1488. PubMed ID: 33556420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
    Wolf M; Swaisland H; Averbuch S
    Clin Cancer Res; 2004 Jul; 10(14):4607-13. PubMed ID: 15269131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.